United States: More Than The Leaves Are Changing: Clinical Trial Research Regulations And Policies Get A Fall Makeover

These changes represent a new season of responsibilities for those who manage and oversee clinical trials.

The Food and Drug Administration (FDA) and National Institutes of Health (NIH) have recently finalized or signaled intent to finalize numerous proposals that promise to change the landscape of clinical trial reporting, clinical researcher responsibility and Institutional Review Board (IRB) oversight. These federal agencies have been busy tidying up existing policies and implementing various requirements to promote better practices in clinical trial research. So what is shaking from the trees? This article provides an overview of the recent proposals and regulations for clinical research.

FDA Draft Guidance for Institutional Review Boards

The Office for Human Research Protections (OHRP) and the FDA have proposed new draft guidance on the written policies and procedures that an IRB should maintain. Although the draft guidance is not binding on IRBs, it provides significant insight into OHRP and FDA expectations for IRB policies and procedures and references specific statutory and regulatory requirements that should be included. The draft guidance is a user-friendly, comprehensive checklist with questions about each policy area, and IRBs are encouraged to take a fresh look at their policies and procedures with this draft guidance in mind.

Clinical Trials Registration and Results Information Submission

Almost two years after its proposed rulemaking, the U.S. Department of Health and Human Services (HHS) issued a final rule for the reporting of clinical trial information on clinicaltrials.gov. Effective January 18, 2017, clinical trial sponsors must register online within 21 days of enrolling the first trial participant. Study sponsors should be aware of this new reporting requirement, as it broadens the breadth of information they must report about the clinical trial.

One of the most critical aspects relates to reporting results about the clinical trial, if collected. Study sponsors will now be required to disclose information regarding outcomes, testing, participant characteristics and adverse events. This information also will be available regardless of whether the study results in a marketed product. The rule applies to an "applicable clinical trial," which typically includes studies on biological devices, drugs and other products subject to FDA oversight.

Revisions to the Common Rule

The clinical research community is anxiously awaiting finalized revisions to the long-standing "Common Rule" governing the protection of human subjects in research and HHS has signaled that a final rule will be released before the end of 2016. HHS and 15 other federal departments and agencies issued a proposed rulemaking on September 8, 2015.  The subject of more than 2,000 comments, the proposed rule is largely in response to recent advances in technology and the evolving use of multiple research sites for clinical trials. Public comments from researchers, institutions and the public generally disagreed with many of the rule's proposals, including a redefinition of "biospecimen" as a "human subject" and a controversial overhaul of the informed consent process. For additional information about these and other proposed changes to the Common Rule, please see the May 31, 2016, May 17, 2016, and September 28, 2015, postings to the Health Law Update blog.

Use of Single IRBs for NIH-Funded Studies

In an effort to streamline administrative processes and create greater reporting efficiency, the NIH recently finalized a new policy that requires a single IRB for purposes of all ethical reviews required by HHS regulations and policies. Applicable to studies involving NIH-funded, non-exempt human subject research conducted across multiple sites, the new policy is effective for all applications submitted on or after May 25, 2017. Under the new requirements, an applicant submitting a request for NIH funding for a multi-site study will be required to submit a plan selecting a site as the IRB of record for all study sites. An applicant may request additional funding to help it comply with the NIH requirements. The IRB of record and the other participating sites must ensure appropriate coordination regarding local regulatory requirements and contextual issues.

Investigator and Research Staff Training on Good Research Practices

In a recent notice, the NIH instituted a new policy that requires all NIH-funded clinical investigators and staff to complete training in Good Clinical Practice effective January 2017. Building on existing training for the protection of human research participants, the NIH is adding specific training on best clinical practices. Investigators and their staff may receive the training through a course, academic training program, or certification from a recognized clinical research professional organization. Participants will be required to complete the training every three years and maintain documentation evidencing such trainings. While the new policy is specific to NIH-funded clinical trials, IRBs may nevertheless consider reviewing their policies and procedures in light of this new training requirement.

Try Not to Fall Back Into Old Habits

These changes represent a new season of responsibilities for those who manage and oversee clinical trials. IRBs, clinical research organizations and investigators have an unprecedented opportunity to get an early start on implementing the new requirements to ensure compliance. So now is the time to rake up those outdated policies and procedures to make way for the new clinical research regulatory landscape.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions